Keytruda

(pembrolizumab)
4 ML pembrolizumab 25 MG/ML Injection [Keytruda]pembrolizumab 50 MG Injection [Keytruda]
NO BLACK BOX WARNING

Dosage & administration

eficacy, safety & testing

Keytruda clinical details

Mechanism of Action (MOA)
PD-L1 Testing
MSI/MMR Testing
TMB Testing
Dosing
Preparation, Storage & Administration
Dose Modifications
Selected Adverse Reactions
Treatment Monitoring & Management
Efficacy: Advanced Melanoma
Safety Profile: Advanced Melanoma
Efficacy: Adjuvant Therapy for Stage IIB, Stage IIC, or Stage III Melanoma
Safety Profile: Adjuvant Therapy for Stage IIB, Stage IIC, or Stage III Melanoma
Efficacy: First-line Combination Therapy in Nonsquamous mNSCLC
Safety Profile: First-line Combination Therapy in Nonsquamous mNSCLC
Efficacy: First-line Combination Therapy in Squamous mNSCLC
Safety Profile: First-line Combination Therapy in Squamous mNSCLC
Efficacy: First-line Monotherapy for Nonsquamous and Squamous Advanced NSCLC
Safety Profile: First-line Monotherapy for Nonsquamous and Squamous Advanced NSCLC
Efficacy: Second-line or Greater Monotherapy for Nonsquamous and Squamous mNSCLC
Safety Profile: Second-line or Greater Monotherapy for Nonsquamous and Squamous mNSCLC
Efficacy: First-line Combination Therapy in Metastatic or Unresectable, Recurrent HNSCC
Safety Profile: First-line Combination Therapy in Metastatic or Unresectable, Recurrent HNSCC
Efficacy: First-line Monotherapy in Metastatic or Unresectable, Recurrent HNSCC
Safety Profile: First-line Monotherapy in Metastatic or Unresectable, Recurrent HNSCC
Efficacy: Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
Safety Profile: Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
Efficacy: Refractory or Relapsed PMBCL
Safety Profile: Refractory or Relapsed PMBCL
Efficacy: First-line Monotherapy for Advanced Urothelial Carcinoma
Safety Profile: First-line Monotherapy for Advanced Urothelial Carcinoma
Efficacy: Second-line Monotherapy—Post–Platinum Failure
Safety Profile: Second-line Monotherapy—Post–Platinum Failure
Efficacy: High-Risk Non-muscle Invasive Bladder Cancer
Safety Profile: High-Risk Non-muscle Invasive Bladder Cancer
Efficacy: Advanced MSI⁠-⁠H/dMMR Cancers
Safety Profile: Advanced MSI⁠-⁠H/dMMR Cancers
Efficacy: Advanced Gastric or GEJ Cancer
Safety Profile: Advanced Gastric or GEJ Cancer
Efficacy: Advanced MSI⁠-⁠H/dMMR CRC
Safety Profile: Advanced MSI⁠-⁠H/dMMR CRC
Efficacy: Advanced Esophageal or GEJ Carcinoma
Safety Profile: Advanced Esophageal or GEJ Carcinoma
Efficacy: First-line Combination Therapy for Advanced Cervical Cancer
Safety Profile: First-line Combination Therapy for Advanced Cervical Cancer
Efficacy: Second-line Monotherapy for Advanced Cervical Cancer
Safety Profile: Second-line Monotherapy for Advanced Cervical Cancer
Efficacy: Advanced Merkel Cell Carcinoma
Safety Profile: Advanced Merkel Cell Carcinoma
Efficacy: Adjuvant Treatment for Renal Cell Carcinoma
Safety Profile: Adjuvant Treatment for Renal Cell Carcinoma
Efficacy: Advanced Renal Cell Carcinoma
Safety Profile: Advanced Renal Cell Carcinoma

drug label

Keytruda prescribing information

Have more Keytruda questions?

Submit MSL Request
Learn More

Need to report a Keytruda issue?

ONLINE FORM
Report adverse event
Learn More

prior authorization

Keytruda Prior authorization resources

NOT PROVIDED BY BRAND
Complete Letter of Medical Necessity
Coverage Authorization Request
Coverage Authorization Appeals
Learn More

Benefits investigation

2022 Merck Access Program Enrollment Form
2023 Merck Access Program Enrollment Form
Merck Access Program - 2023 Healthcare Provider Enrollment Form
2022 Merck Access Program Electronic Enrollment Form
2023 Merck Access Program Electronic Enrollment Form
Merck Access Program - 2023 Healthcare Provider Electronic Enrollment Form
Learn More

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information
Learn More

financial assistance

Keytruda Financial assistance options

Co-pay savings program

commercial only
2022 Merck Access Program Enrollment Form
2023 Merck Access Program Enrollment Form
Merck Access Program - 2023 Healthcare Provider Enrollment Form
2022 Merck Access Program Electronic Enrollment Form
2023 Merck Access Program Electronic Enrollment Form
Merck Access Program - 2023 Healthcare Provider Electronic Enrollment Form
Enroll in Patient Savings Program
Learn More

Bridge program

commercial only
Learn More

Foundation programs

under insured
no insurance
goverment insurance
65+
2022 Merck Access Program Enrollment Form
2023 Merck Access Program Enrollment Form
Merck Access Program - 2023 Healthcare Provider Enrollment Form
2022 Merck Access Program Electronic Enrollment Form
2023 Merck Access Program Electronic Enrollment Form
Merck Access Program - 2023 Healthcare Provider Electronic Enrollment Form
Merck Patient Assistance Program Application
Learn More

patient education

Keytruda Patient education

Getting started on Keytruda

NOT PROVIDED BY BRAND
Instructions For Use: Advanced Melanoma

NOT PROVIDED BY BRAND
Instructions For Use: Adjuvant Therapy for Stage IIB, Stage IIC, or Stage III Melanoma

NOT PROVIDED BY BRAND
Instructions For Use: First-line Combination Therapy in Nonsquamous mNSCLC

NOT PROVIDED BY BRAND
Instructions For Use: First-line Combination Therapy in Squamous mNSCLC

NOT PROVIDED BY BRAND
Instructions For Use: First-line Monotherapy for Nonsquamous and Squamous Advanced NSCLC

NOT PROVIDED BY BRAND
Instructions For Use: Second-line or Greater Monotherapy for Nonsquamous and Squamous mNSCLC

NOT PROVIDED BY BRAND
Instructions For Use: Subsequent-line Monotherapy in Recurrent or Metastatic HNSCC

NOT PROVIDED BY BRAND
Instructions For Use: First-line Combination Therapy in Metastatic or Unresectable, Recurrent HNSCC

NOT PROVIDED BY BRAND
Instructions For Use: First-line Monotherapy in Metastatic or Unresectable, Recurrent HNSCC

NOT PROVIDED BY BRAND
Instructions For Use: Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)

NOT PROVIDED BY BRAND
Instructions For Use: Refractory or Relapsed PMBCL

NOT PROVIDED BY BRAND
Instructions For Use: First-line Monotherapy for Advanced Urothelial Carcinoma

NOT PROVIDED BY BRAND
Instructions For Use: Second-line Monotherapy—Post–Platinum Failure

NOT PROVIDED BY BRAND
Instructions For Use: High-Risk Non-muscle Invasive Bladder Cancer

NOT PROVIDED BY BRAND
Instructions For Use: Advanced MSI⁠-⁠H/dMMR Cancers

NOT PROVIDED BY BRAND
Instructions For Use: Advanced Gastric or GEJ Cancer

NOT PROVIDED BY BRAND
Instructions For Use: Advanced MSI⁠-⁠H/dMMR CRC

NOT PROVIDED BY BRAND
Instructions For Use: Advanced Esophageal or GEJ Carcinoma

NOT PROVIDED BY BRAND
Instructions For Use: First-line Combination Therapy for Advanced Cervical Cancer

NOT PROVIDED BY BRAND
Instructions For Use: Second-line Monotherapy for Advanced Cervical Cancer

NOT PROVIDED BY BRAND
Instructions For Use: Advanced Hepatocellular Carcinoma

NOT PROVIDED BY BRAND
Instructions For Use: Advanced Merkel Cell Carcinoma

NOT PROVIDED BY BRAND
Instructions For Use: Adjuvant Treatment for Renal Cell Carcinoma

Patient toolkit

NOT PROVIDED BY BRAND
Not Provided By Brand
Learn More

people also ask

Keytruda FAQs

FAQ Data Source

Can't find what you're looking for?

Our trained staff can help you:
Please note:
  • Access to a Field Reimbursement Manager (FRM) or Medical Science Liaison (MSL) varies by brand and may require talking with your rep first.
  • Samples are provided at the discretion of the brand.
  • We are unable to collect Protected Health Information (PHI), fill out forms, or submit them on your behalf.